The 41st Annual General Meeting of Zim Laboratories Limited was held on Friday, June 27, 2025, via video conferencing.
The meeting commenced at 11:30 a.m. IST and concluded at 12:53 p.m.
The Company Secretary welcomed the members and provided instructions regarding participation and e-voting.
The Chairman addressed the members on the company's performance for FY 2024-25.
Resolutions were presented, including the adoption of financial statements, appointment/re-appointment of directors and auditors, and ratification of remuneration.
Members who have registered themselves as speakers for the AGM asked questions or expressed their views.
E-voting results will be declared on the company website and intimated to the stock exchanges.
Zulfiquar Kamal, a promoter of ZIM Laboratories Limited, has declared that neither he nor any persons acting in concert have encumbered any shares, directly or indirectly, during the financial year ended March 31, 2025.
ZIM Laboratories Limited has issued a corrigendum to its Annual Report for the financial year 2024-25 due to inadvertent typographical errors in the Corporate Governance Report and the Independent Auditors Report.
The revised Annual Report, along with the Notice of the 41st AGM to be held on Friday, 27th June, 2025 at 11.30 a.m. (IST) via Video Conference / Other Audio Visual Means, has been submitted to the stock exchanges and uploaded on the company's website.
The company confirms that no other changes were made to the Annual Report besides the mentioned corrections.
In FY25, Total Operating Income grew by 3.2% YoY, reaching ₹37,900 Mn, primarily driven by increased contributions from Innovative Products. EBITDA grew by 6.4% YoY to ₹4,950 Mn, with an EBITDA margin of 13.1%, while Profit After Tax (PAT) stood at ₹1,220 Mn, translating to a PAT margin of 3.2%.
Export Revenue grew by 8.9% YoY to ₹31,250 Mn, up from ₹28,700 Mn in FY24, supported by robust demand across key international markets.
Revenue from NIP + OTF stood at ₹7,220 Mn, reflecting a 65% YoY growth and contributing 19% to Total Operating Income, inclusive of licensing income.
R&D expenditure accounted for 8.8% of Total Operating Income, in line with the company's strategy towards innovation and proprietary technology development.
Finance costs increased from ₹69 Mn to ₹114 Mn, mainly due to higher borrowings for plant and equipment upgrades, which rose from ₹10,64 Mn to ₹11,22 Mn.
NIP+OTF Dossier Licensing Income rose to ₹98 Mn, indicating strong monetisation of ZIM's Innovative Products and enhanced licensing capabilities.
Completed CapEx projects for Urology Suite and Nutraceutical Suite, significantly enhancing manufacturing capabilities
Expansion in International Markets through Scientific Office in the UAE and collaboration with local partner in the UAE.
Received the first EU Marketing Authorisation for Azithromycin Oral Suspension (NIP category) and secured the second EU Marketing Authorisation for Dimethyl Fumarate (NIP category) in Portugal.
Completed 23 NIP filings for 6 molecules, including 5 filings for 4 molecules in the EU, 1 filing in Australia, and 17 filings in Pharmerging & RoW; 14 filings under ZIM’s name.
Completed 17 OTF filings for 5 molecules—6 filings for 2 molecules in the EU, 1 in Australia, and the rest 10 filings across Pharmerging and RoW markets; 3 filings under ZIM's name.
Received 6 NIP MAs for 3 molecules - 2 in the EU & 4 in Pharmerging & RoW Markets and received 7 OTF MAs for 5 molecules - 1 EU - wide & 6 across Pharmerging & RoW Markets